Nomura says Rohto earnings may top guidance on sales momentum
Nomura analysts said Rohto Pharmaceutical’s earnings for the fiscal year may beat its full-year guidance, citing strong momentum for its mainstay brands in Japan and overseas.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.